Phase 2 trial of lenvatinib and everolimus in metastatic renal cell carcinoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London, UK, discusses the results of a phase 2, three-arm trial of lenvatinib, everolimus, and lenvatinib plus everolimus in patients with metastatic renal cell carcinoma.

Year of Production:
Running Time:
Color/Sound:

2015
01:31
Color/Sound

Comments are closed.